Related coverage linked through entity extraction aliases.
Apr 27, 2026
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
Apr 25, 2026
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Apr 24, 2026
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
Apr 24, 2026
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Apr 24, 2026
A meta-analysis in BMC Ophthalmology found distinct gut microbiome compositional and functional alterations in diabetic retinopathy. The review identified depleted SCFA-producing bacteria, enriched pro-inflammatory bacteria, and dysregulated metabolic pathways.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 22, 2026
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Apr 22, 2026
Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.
Apr 21, 2026
Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Apr 19, 2026
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Apr 18, 2026
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
Apr 17, 2026
The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion to USD 5.73 billion by 2035 at a 19% CAGR. Monoclonal antibodies hold almost 55% of market share, while oncological disorders dominate demand.
Apr 17, 2026
Europe's infusion pump market is projected to reach USD 7.09 billion by 2031 at a 6.8% CAGR. Growth is driven by connected systems, tighter safety standards, homecare use, and diabetes demand.
Apr 12, 2026
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
Apr 08, 2026
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Apr 08, 2026
Researchers have used a machine learning model called AI-IR to demonstrate that insulin resistance is a risk factor for 12 types of cancer. The tool analyzes nine clinical parameters from standard health checkups to predict insulin resistance at population scale. This provides the first large-scale evidence linking insulin resistance to multiple cancers.
Apr 07, 2026
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Apr 06, 2026
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
